top of page

The Latest Buzz

Fetch! Doge bringing the newspaper

Houston Start-up Tackles Dog Cancer

Listen to our CEO talk about cancer in our pets and how CAVU is solving this problem on NPR's Bauer Business Focus.

December 20, 2017


Houston, TX– CAVU Biotherapies was recently recognized as one of the “Best Entrepreneurial Companies in America” by Entrepreneur magazine’s Entrepreneur360™ List, a premier study delivering the most comprehensive analysis of private companies in America. Based on this study forged by Entrepreneur, CAVU Biotherapies is recognized as a well-rounded company that has mastered a balance of impact, innovation, growth and leadership.


"I am thrilled to have CAVU recognized as one of the best entrepreneurial companies in America.  It is a testimony to great teamwork, the city of Houston's entrepreneurial support,  and the passion to help our dogs overcome cancer through new personalized therapies," stated Dr. Colleen O'Connor, CEO of CAVU Biotherapies.

“Our annual evaluation is a 360-degree analysis of top privately-held companies representing and serving a variety of industries,” explains Lisa Murray, Chief Insights Officer of Entrepreneur Media, Inc. “These businesses are real-world case studies for any entrepreneur who seeks to master the four pillars that can greatly impact the longevity and growth of their businesses. With the Entrepreneur 360, success is measured by achieving balance throughout the entire organization, predicated by revenue.”


CAVU Biotherapies is a Houston, TX-based, USDA authorized, veterinary biotech company focused on modernizing cancer care for dogs using personalized therapies with veterinary oncology providers located in California, Texas, and Florida. CAVU's services enable owners to plan ahead for their dogs T-cell based cancer care and veterinarians to tailor treatments to the individual by using greater knowledge of the patient's immune system.


Honorees were identified based on the results from a comprehensive study of independently- owned companies, using a proprietary algorithm and other advanced analytics. The algorithm was built on a balanced scorecard designed to measure four metrics reflecting major pillars of entrepreneurship—innovation, growth, leadership and impact.


To learn more about CAVU Biotherapies, visit:


For additional details on the E360 List and the companies recognized, visit:

July 25, 2017

CEO and Founder Featured in the award winning book "HEAL: The Vital Role of Dogs In The Search For Cancer Cures"

Dr. O'Connor was featured in the Gold Medal Winner of the 2016 Independent Publishers Book Award, "HEAL" by Arlene Weintraub.  In the book,  Dr. O'Connor explains her extensive experience with canine T-cell therapy and doing the world's first T-cell infusion into a pet dog with cancer,  tumor involved immune system dysfunction, and the development of CAR T-cell therapy for dogs living with cancer.  She talks about how T-cell therapy and immunotherapy is the future for our dogs.

July 09, 2017

CAVU Biotherapies Sets "Fire" to the Competition

CAVU Biotherapies wins at the NexGen Rapid Fire Pitch Competition and proceeds to the second round where we will pitch in front of investors.

June 25, 2017

Dazzling Pitch Wins CAVU Biotherapies 2nd Place Win at Pitch A Kid Houston

CEO, Colleen O'Connor,PhD, uses Star Wars to explain cancer and the immune system to kid judges with success.

June 12, 2017

CAVU Biotherapies Joins Fight to Solve Cancers Shared by Kids and Dogs

There’s some good news coming out of Washington, DC this week for children and pets. I just returned from the Paws for a Cure meeting which was groundbreaking. Those of us working in the word of cancer know that dogs and kids develop many of the same cancers, but efforts to find a cure are not widely shared. We are now working to change that.

1 / 1

Please reload


Social Media Stream

Social Media S
bottom of page